Abstract
We present the results of our experience in the diagnosis of inborn errors of metabolism (IEM) since the Expanded Newborn Screening was implemented in our Region. Dried blood samples were collected 48 h after birth. Amino acids and acylcarnitines were quantitated by mass spectrometry (MS)/MS. Newborns with alterations were referred to the clinical centers for follow‐up. Biochemical and molecular genetic studies for confirmation of a disease were performed. In the period 2011 to 2019, 592 822 children were screened: 902 of them were referred for abnormal results. An IEM was confirmed in 222 (1/2670): aminoacidopathies: 89 hyperphenylalaninemia (HPA) (51 benign HPA, 32 phenylketonuria, 4 DNAJC12 defect, and 2 primapterinuria), 6 hypermethioninemia, 3 tyrosinemia type 1 (TYR‐1), 1 TYR‐3, 4 maple syrup urine disease (MSUD), 2 branched‐chain amino acid transferase 2 deficiency, 2 homocystinuria, 1 cystinuria, 2 ornithine transcarbamylase (OTC) deficiency, 2 citrullinemia type I (CTLN1); FAO defects: 43 medium‐chain acyl‐CoA dehydrogenase deficiency (MCADD), 13 very long‐chain acyl‐CoA dehydrogenase deficiency, 2 long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency (LCHADD), 1 multiple acyl‐coA dehydrogenation deficiency, 11 systemic primary carnitine deficiency, 2 carnitine palmitoyltransferase type 2 (CPT‐II) deficiency, 1 CPT‐I deficiency; organic acidurias: 12 glutaric aciduria type 1 (GA‐1), 4 methylmalonic acidemia (MMA), 7 MMA including combined cases with homocystinuria (MMAHC), 6 propionic acidemia (PA), 7 3‐methylcrotonyl‐CoA carboxylase, 1 3‐hydroxy‐3‐methylglutaryl‐CoA lyase deficiency lyase deficiency. Only 19 infants (8.5%) were symptomatic at newborn screening result (1 LCHADD, 5 PA, 1 CPT‐II deficiency, 1 MMA, 3 MMAHC, 2 MSUD, 2 OTC deficiency, 1 CTLN1, 1 MCADD, 2 TYR‐1). No false negative cases were identified. Genetic diagnosis was conclusive in all biochemically confirmed cases, except for two infants with HPA, identifying pathogenic variants in 32 different genes. The conditions with the highest incidence were HPA (1/6661) and MCAD deficiencies (1/13 787).
Keywords: inborn error of metabolism, neonatal screening, tandem mass spectrometry
Synopsis.
After the expanded newborn screening, 222 inborn errors of metabolism have been diagnosed in the Madrid Region, 203 of them in a presymptomatic phase.
1. INTRODUCTION
Newborn screening (NBS) started in the early 1960s with Robert Guthrie. 1 In our country, the first NBS program was implemented in Granada in 1968 on the initiative of Prof Federico Mayor Zaragoza. 2 Since then, programs have certainly improved as new technologies have evolved, especially after the introduction of tandem mass spectrometry (MS/MS) in the early 1990s. 3 , 4 MS/MS allows the simultaneous quantification of multiple analytes with high sensitivity and specificity, therefore it has been incorporated for inborn errors of metabolism (IEM) screening, providing the capability to detect over 50 conditions. 5 However, countries have different approaches, and the situation varies considerably worldwide. 6 In North America, a specific screening including which minimum IEM is established in all states. 7 However, in the European Union, there is no agreement about which IEM should be screened. 8 Furthermore, the protocols of the different countries vary in numerous aspects, from specimen collection to diagnosis, organization, follow‐up, and treatment. 9 In Spain, as in other European Countries such as Belgium, Bosnia‐Herzegovina, Germany, Italy, or United Kingdom, the NBS program is carried out under the responsibility of different regions of the country. 10 In 2013, the Spanish National Health System included, as mandatory, screening for seven genetic disorders, including four IEM (phenylketonuria [PKU], medium‐chain acyl‐CoA dehydrogenase deficiency [MCADD], long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency [LCHADD], and glutaric aciduria type 1 [GA‐1]). 11 However, in practice, NBS is determined by the policies of individual regions, so there is a lack of uniformity in testing for disorders at birth around the country. 12 , 13 In the Community of Madrid, expanded NBS (ENBS) with MS/MS was initiated in 2011, including 17 metabolic disorders. 14 In this article, the results of 9 years' experience in the diagnosis of IEM, after the implementation of the ENBS in our region, are described. Clinical and demographic data of the patients, along with the biochemical and the molecular characterization are presented.
2. PATIENTS AND METHODS
Metabolic disorders included in our ENBS program were: benign hyperphenylalaninemia (HPA)/ PKU, tyrosinemia type 1 (Tyr‐1), maple syrup urine disease (MSUD), MCADD, LCHADD, very long‐chain acyl‐CoA dehydrogenase deficiency, systemic primary carnitine deficiency (SPCD), 3‐hydroxy‐3‐methylglutaryl‐CoA lyase deficiency (HMG‐CoA lyase deficiency), GA‐1, methylmalonic acidemia (MMA) including combined cases with homocystinuria (MMAHC), propionic acidemia (PA), isovaleric acidemia, and beta‐ketothiolase deficiency. Furthermore, the different metabolites analyzed allows the identification of other IEM, such as homocystinuria, tyrosinemia type III, 3‐methylcrotonyl‐CoA carboxylase deficiency (MCG‐3), and some urea cycle defects, which are reported when detected, although not included “per se” in the program.
Dried blood samples were collected 48 h after birth and dried at room temperature. Amino acids, acylcarnitines, and succinylacetone were quantitated by NeoBase non‐derivatized MS/MS kit (PerkinElmer, Turku, Finland) from March 2011 to August 2018 and NeoBase 2 non‐derivatized MS/MS kit (PerkinElmer) from that moment to December 2019. Tandem mass spectrometer employed was an Acquity TDQ UPLC/MS (Waters, Milford, MA) system. For data acquisition and processing, the applications MassLynx (Waters), Neolynx and Specimen Gate MSMS Data Suite (PerkinElmer) were used. Our program analytes and ratios were selected following the Clinical and Laboratory Standards Institute recommendation. 15 Cut‐off values were reviewed periodically. When the result for a newborn sample was flagged as above or under the cut‐off value (99.5th or 1st percentile), the analysis was repeated in duplicate before it was reported. If the repeat test was slightly outside the normal range, a second sample was requested by the NBS laboratory. On the other hand, if the result was clearly pathological, the patient was referred to one of the four reference clinical centers distributed by demographic criteria (Hospital Universitario 12 de Octubre, Hospital Universitario Ramón y Cajal, Hospital Universitario La Paz, Hospital Infantil Universitario Niño Jesús) for management, counseling, and follow‐up. Afterward, serum and urine samples were referred to the biochemical and molecular genetic laboratory (Centro de Diagnóstico de Enfermedades Moleculares), where they performed biochemical studies for confirmation of a disease, including plasma amino acids, acylcarnitines, urinary organic acid profiles, and molecular diagnosis thereafter to confirm the defect. Variants were classified following American College of Medical Genetics guidelines. 16
In this study, we have included all the patients diagnosed with an IEM, who were referred to the clinical units for an abnormal screening between March 8, 2011 when ENBS was established in the Community of Madrid, and December 31, 2019.
Demographic and clinical conditions of the patients were registered, including sex, gestational age, presence or not of consanguinity, parents' country of origin, presence or not of symptoms at the time of the NBS result, biochemical and molecular diagnose, and if death occurred due to their pathology.
All these data were statistically analyzed with SPSS Statistics 24.
3. RESULTS
During the period included, 592.822 children were included in the ENBS program, 902 of them were referred due to an abnormal screening result. An IEM was confirmed in 222 cases (Table 1), which means an incidence of one case per 2.670 newborns (1/2670). Cases referred to the units without an IEM diagnosis are not included in this study and they correspond mostly to false positives cases, transitional alterations, heterozygote carriers, or vitamin B12 deficiency. The positive predictive value for the diagnosis of an IEM was 24.6%.
TABLE 1.
Demographic, clinical, and biochemical data of patients diagnosed with an IEM by newborn screening in Madrid. Incidence is only shown for conditions included in the program
| Biochemical diagnosis | MIM | Gene | GEN MIM | No. cases | Incidence | Days to clinical referral in asymptomatic patients mean (range) | Number of newborns with clinical symptoms before diagnosis (%) | Biochemical finding (median [range]) |
|---|---|---|---|---|---|---|---|---|
| Disorders of amino acid metabolism | ||||||||
| Benign HPA | 261 600 | PAH | 612 349 | 52 | 1/11 400 | 20.5 [7–117] | 0 |
Phe: 172.8 μmol/L [97.5–244.2] Phe/Tyr: 2.1 [1.2–5.6] |
| Classic PKU | 261 600 | PAH | 612 349 | 32 | 1/18 525 | 10.8 [5–41] | 0 |
Phe: 576.8 μmol/L [225–1950] Phe/Tyr: 11.9 [1.8–32.2] |
| DNAJC12 deficiency | 261 600 | DNAJC12 | 606 060 | 4 | NA | NA | 0 |
Phe: 162.4 [123.1–265.0] Phe/Tyr: 1.8 [1.6–2.0] |
| Primapterinuria | 264 070 | PCBD1 | 126 090 | 2 | 1/296 411 | 12.5 [11–14] | 0 |
Phe: 480, 193.4 μmol/L Phe/Tyr: 193.4, 3.6 |
| GA1 | 231 670 | GCDH | 600 225 | 12 | 1/49 402 | 9.8 [5–30] | 0 | C5DC: 2.72 μmol/L [0.36–5.17] |
|
MCG‐3‐MCC1D MCC2D |
210 200 210 210 |
MCCC1 MCCC2 |
609 010 609 014 |
2 5 |
1/846 89 | 21.2 [7–58] | 0 | C5OH: 2.4 μmol/L [0.9–5.8] |
| PA | 606 054 | PCCB | 232 050 | 6 | 1/98 804 | 9.5 [6–15] | 5 (83%) |
C3: 11.4 μmol/L [7.5–13.8] C3/C2: 0.9 [0.17–2.03] C3/Met: 0.9 [0.3–1.2] |
| MAT | 250 850 | MAT1A | 610 550 | 6 | NA | 18.7 [9–41] | 0 | Met: 87.3 μmol/L [53–121] |
|
TYR‐TYRSN1 |
276 700 | FAH | 613 871 | 3 | 1/197 607 | 6.7 [6–8] | 1 (33.3%) |
Tyr: 152.4 μmol/L [107.20–198] SA: 12.69 μmol/L [11.46–13.70] |
| TYRSN3 | 276 710 | HPD | 609 695 | 1 | NA | 13 | 0 |
Tyr: 558 mmol/L SA: 0.49 μmol/L |
|
MSUD |
248 600 | BCKDHB | 248 611 |
2 |
1/197 607 |
25.5 [8–43] |
3 (75%) |
Leu + Ile + Hyp: 1182 μmol/L [359–1911] Val: 375 μmol/L [137–616] |
|
248 600 |
BCKDHA | 608 348 |
1 |
|||||
| DBT | 248 610 |
1 |
||||||
| BCAT‐2 deficiency | 618 850 | BCAT2 | 113 530 | 2 | NA | 11 [9–13] | 0 |
Leu + Ile + Hyp: 298, 686 μmol/L Val: 312, 543 μmol/L |
| HC | 236 200 | CBS | 613 381 | 2 | NA | 11.5 [10–13] | 0 | Met: 58.1, 92.0 μmol/L |
| Cystinuria | 220 100 | SLC3A1 | 104 614 | 1 | NA | 21 | 0 | C3/C2: 0.24 μmol/L |
| OTC | 311 250 | OTC | 300 461 | 1 | NA | NA | 1 (100%) | Cit: 2.5 μmol/L |
| CTLN1 | 215 700 | ASS1 | 603 470 | 2 | NA | 11 | 0 | Cit: 155, 1010 μmol/L |
| HMGCLD | 246 450 | HMGCL | 613 898 | 1 | NA | NA | 0 | C5OH: 0.8 μmol/L |
| Disorders of fatty acid oxidation and transport (FAO) | ||||||||
| MCADD | 201 450 | ACADM | 607 008 | 43 | 1/13 787 | 11.3 [4–47] | 1 (2.7%) |
C8: 9.3 μmol/L [0.4–41.2] C8/C10: 10.4 [0.7–15.5] |
| VLCAD | 201 475 | ACADVL | 609 575 | 13 | 1/45 602 | 12.4 [7–26] | 0 | C14:1:2.6 μmol/L [0.6–7.5] |
| LCHADD | 609 016 | HADHA | 600 890 | 2 | 1/296 411 | 7 | 1 (50%) |
C14:1:0.7, 0.7 μmol/L C16OH: 0.4, 0.8 μmol/L C18:OH: 0.5, 1.1 μmol/L |
| SPCD | 212 140 | SLC22A5 | 603 377 | 11 | 1/53 893 | 43.2 [8–128] | 0 | C0: 3.8 μmol/L [2.9–5.1] |
| CPT II | 600 649 | CPT2 | 600 650 | 2 | NA | 20 | 1 (50%) |
C12: 0.6, 0,7 μmol/L C14: 1.6, 2.0 μmol/L C16:1:2.5, 2.7 μmol/L C18: 5.9, 5.7 μmol/L |
| MADD | 231 680 | ETFB | 130 410 | 1 | 1/592 822 | 5 | 0 |
C8: 0.6 μmol/L C12: 1.9 μmol/L C14:1:1.7 μmol/L C16:OH: 0.5 μmol/L |
| CPT I | 255 120 | CPT1A | 600 528 | 1 | NA | 11 | 0 |
C0: 94.7 μmol/L C16‐C18/C0: 160.5 |
| Disorders of cobalamin metabolism | ||||||||
| MMAHC | 277 400 | MMACHC | 609 831 |
6 |
1/84 689 | 20.4 [6–54] | 3 (43%) |
C3: 6.8 μmol/L [2.8–9.4] C3/C2: 0.71 [0.22–1.83] C3/Met: 1.07 [0.24–2.21] |
| 277 410 | MMADHC | 611 935 | 1 | |||||
| MMA | 251 000 | MMUT | 609 058 |
2 |
1/148 205 | 30.7 [19–38] | 1 (25%) |
C3: 6.30 μmol/L [3.9–9.1] C3/C2: 0.34 [0.24–0.6] C3/Met: 0.39 [0.22–0.72] |
| 251 110 | MMAB | 607 568 | 2 | |||||
Abbreviations: BCAT‐2, branched‐chain amino acid transferase 2 deficiency; CPT‐I, carnitine palmitoyltransferase type 1 deficiency; CPT‐II, carnitine palmitoyltransferase type 2 deficiency; CTLN1, citrullinemia type 1; DNAJC12, hyperphenylalaninemia due to DNAJC12 defect; GA‐1, glutaric aciduria type 1; HC, homocystinuria; HMG‐CLD, 3‐hydroxy‐3‐methylglutaryl‐CoA lyase deficiency; HPA, hyperphenylalaninemia; Hyp, Hydroxyproline; Ile, Isoleucine; LCHADD, long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency; Leu, Leucine; MADD, multiple acyl‐coA dehydrogenation deficiency; MAT, hypermethioninemia; MCADD, medium‐chain acyl‐CoA dehydrogenase deficiency; MCG‐3:3‐methylcrotonyl‐CoA carboxylase deficiency; MMA, methylmalonic acidemia; MMAHC, methylmalonic acidemia with homocystinuria; MSUD, maple syrup urinary disease; NA, not applicable; OTC, ornithine transcarbamylase deficiency; PA, propionic acidemia; PKU, phenylketonuria; SPCD, systemic primary carnitine deficiencies; TYRSN‐1, tyrosinemia type I; TYRSN‐3, tyrosinemia type 3; VLCAD, very long‐chain acyl‐CoA dehydrogenase deficiency.
IEM diagnosis included in the NBS program were 89 HPA (51 benign HPA, 32 classic PKU, 4 DNAJC12 defects, and 2 primapterinuria), 3 Tyr‐1, 4 MSUD, 43 MCADD, 2 LCHADD, 13 VLCAD, 11 SPCD, 12 GA‐1, 4 MMA, 7 MMAHC (6 cblC, 1 cblD), 6 PA, and 1 HMG‐CoA lyase deficiency. No cases of isovaleric acidemia nor beta‐ketothiolase deficiency were detected. Other metabolic conditions detected were: 6 hypermethioninemia, 1 tyrosinemia type 3, 2 branched‐chain amino acid transferase 2 deficiencies (BCAT‐2), 2 homocystinuria (cystathionine beta‐synthase deficiencies), 1 cystinuria, 2 ornithine transcarbamylase (OTC) deficiencies, 2 citrullinemia type I (CTLN1), 1 multiple acyl‐coA dehydrogenation deficiency (MADD), 2 carnitine palmitoyltransferase type 2 (CPT‐II) deficiency, 1 CPT 1 deficiency (CPT‐I), and 7 MCG‐3 (Table 1).
Of the total number of cases, 122 neonates were girls (55%). Median time to consultation in the clinical centers was 11 days of life (interquartile range: 8–17), being different according to the different pathologies as shown in Table 1. Nineteen of the patients (8.2%) had consanguineous parents and homozygous variants.
Only 19 infants (8.5%) were symptomatic at the time of the NBS result (1 LCHADD, 5 PA, 1 CPT‐II, 1 MMA, 3 MMAHC, 2 MSUD, 2 OTC deficiency, 1 CTLN1, 1 MCADD, 2 TYR‐1), displaying different clinical presentations and evolutions (Table 2). Three patients died due to their metabolic disorder, all of them had been detected in a symptomatic phase. One patient with LCHADD and one with OTC deficiency died in the first year of life. The other patient suffered from PA, he died at 3.5 years from a metabolic decompensation. So far, false negative cases have not been identified.
TABLE 2.
Summary of patients who displayed with clinical symptoms before the newborn screening results were available
| Case | IEM | NBS biochemical markers | Genotype | Days of life presenting with symptoms | Health care provider contact prior to NBS result | Clinical manifestations at diagnosis | Biochemical abnormalities | Detoxification measures at diagnosis | Long‐term follow‐up. Comorbidities |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LCHAD | C16:1:0.41 μmol/L |
HADHA: c.453 + 1G > A (p.?)/c.453 + 1G > A (p.?) |
1 | Yes | Acute respiratory distress and poor perfusion of peripheral tissues (dilated cardiomyopathy) | Hypoglycemia, metabolic acidosis, elevated lactate (12.1 mmol/L), hyperammonemia (134 μmol/L), CPK elevation (7.130 U/L) | Glucose 10 mg/kg/min and bicarbonate infusion | Death at 6 months |
| 2 | MCADD | C8: 41.2 μmol/L C8/C10: 15.5 |
ACADM c.985A > G (p.Lys329Glu)/c.985A > G (p.Lys329Glu) |
2 | No | Hypotonia | Hypoglycemia | No | No clinical alterations or metabolic decompensations |
| 3 | CPT‐II |
C12: 0.7 μmol/L C14: 2.1 μmol/L C16:1:2.7 μmol/L C18: 5.7 μmol/L |
CPTII c.1547 T > C (p.Phe516Ser)/c.122_130del9 (p.Pro41_Met43del) |
7 | No | Acute encephalopathy and seizures | Hypoglycemia, hyperammonemia (583 μmol/L) | Glucose 10 mg/kg/min | Autism spectrum disorder |
| 4 | PA |
C3: 11 μmol/L C3/C2: 1.1 C3/Met: 1.2 |
PCCB c.1218_1231del14ins12 (p.Gly407Argfs*14)/c.1218_1231del14ins12 (p.Gly407Argfs*14) |
2 | Yes | Somnolence | Hypoglycemia, metabolic acidosis, hyperammonemia (480 μmol/L) | Glucose 10 mg/kg/min, arginine, carglumic acid, and ammonia scavengers | Hypotonia, pyramidal syndrome with severe cognitive impairment and epilepsy. Episodes of acute encephalopathy in absence of metabolic decompensation. Death at the age of 3.5 years because of breathing difficulty |
| 5 | PA |
C3: 12.2 μmol/L C3/C2: 0.17 C3/Met: 0.61 |
PCCB c.1218_1231del14ins12 (p.Gly407Argfs*14)/ c.1218_1231del14ins12 (p.Gly407Argfs*14) |
8 | No | Lethargy, hypotonia, and urinary Escherichia coli infection | Metabolic acidosis, ketosis, hyperammonemia (239 μmol/L), pancytopenia | Glucose 10 mg/kg/min, arginine, carglumic acid, and ammonia scavengers |
Several episodes of metabolic decompensation Severe–moderate cognitive impairment Liver transplantation |
| 6 | PA | C3: 12.4 μmol/L C3/C2: 2.0 C3/Met: 1.0 |
PCCB c.1173dupT (p.Val392Cysfs*2)/c.1218_1231del14ins12 (p.Gly407Argfs*14) |
5 | Yes | Encephalopathy and vomiting | Anemia, hyperammonemia (805 μmol/L), metabolic acidosis | Hemodiafiltration, carglumic acid, ammonia scavengers, l‐arginine, cofactors. | Cognitive impairment |
| 7 | PA |
C3: 13.8 μmol/L C3/C2: 1.09 C3/Met: 1.18 |
PCCB c.1218_1231del14ins12 (p.Gly407Argfs*14)/c.1218_1231del14ins12 (p.Gly407Argfs*14) |
7 | Yes | Somnolence, poor feeding | Metabolic acidosis, hyperammonemia (585 μmol/L), anemia, thrombocytopenia, neutropenia | Glucose 10 mg/kg/min, arginine, carglumic acid, and sodium phenylbutyrate | Cognitive impairment and epilepsy |
| 8 | PA |
C3: 14.36 μmol/L C3/C2: 0.67 C3/Met: 0.79 |
PCCB c.1173dupT(p.Val392Cysfs*2)/c.1173dupT(p.Val392Cysfs*2) |
2 | Yes | Somnolence, breathing difficulty | Hypoglycemia, hyperammonemia 7(234 μmol/L) | Glucose 10 mg/kg/min, arginine, and carglumic acid | Liver transplantation |
| 9 | MMAHC | C3: 9.5 μmol/L C3/C2: 0.5 C3/Met: 1.6 |
MMACHC c.271dupA (p.Arg91Lysfs*14)/c.271dupA (p.Arg91Lysfs*14) |
12 | No | Encephalopathy and seizures | Neutropenia | Cobalamin, folinic acid, and betaine | Visual and cognitive impairment |
| 10 | MMAHC | C3:3.80 μmol/L C3/C2: 1.02 C3/Met: 0.65 |
MMACHC c.271dupA (p.Arg91Lysfs*14)/c.271dupA (p.Arg91Lysfs*14) |
18 | No | Somnolence, poor feeding | Hypoglycemia, anemia, thrombocytopenia | Glucose 10 mg/kg/min | Cognitive impairment, epilepsy and growth restriction |
| 11 | MMAHC |
C3: 8.72 μmol/L C3/C2: 0.52 C3/Met: 1.83 |
MMACHC c.271dupA (p.Arg91Lysfs*14) /c.271dupA (p.Arg91Lysfs*14) |
11 | Yes | Cardiomyopathy, hypotonia, seizures, jaundice, eczema, and urinary E. coli infection | Metabolic acidosis | Glucose 10 mg/kg/min | Cognitive impairment, behavioral disorder |
| 12 | MMA | C3: 9.17 μmol/L C3/C2: 0.60 C3/Met: 0.72 |
MMAB c.662 T > G (p.Phe221Cys)/c.569G > A (p.Arg190His) |
13 | No | Mild drowsiness | Metabolic acidosis, elevated lactate (7 mmol/L) | Glucose 10 mg/kg/min |
Several episodes of metabolic decompensation (acidosis) Normal neurodevelopment |
| 13 | MSUD |
Leu: 1390 μmol/L Val: 616 μmol/L |
BCKDHB c.508C > T (p.Arg170Cys)/c.595_596delAG (p.Pro200Ter) |
8 | Yes | Severe encephalopathy (coma), fever, seizures, and facial and perianal eczema | Metabolic acidosis and hypernatremia | Hemodiafiltration | Cognitive impairment and liver transplantation (March 2018) |
| 14 | MSUD |
Leu: 1070 μmol/L Val: 492 μmol/L |
DBT c.(51 + 1_52–1)_(175 + 1_176–1)/c.(51 + 1_52–1)_(175 + 1_176–1) |
6 | Yes | Somnolence, poor feeding |
Ketonuria+++ Mild hyperammonemia (126 μmol/L) |
Hemodiafiltration |
High leucine levels, with few episodes of metabolic decompensation Central nervous system lesions |
| 15 | TRSN1 |
SA: 11.46 μmol/L Tyr: 107.2 μmol/L |
FAH c.554‐1G > T (p.?)/c.554‐1G > T (p.?) |
8 | No | No | Acute hepatic failure: hypoglycemia, coagulopathy | No | Mild cognitive impairment, epilepsy, and attention deficit hyperactivity disorder |
| 16 | TRSN1 |
SA: 13.70 μmol/L Tyr: 152 μmol/L |
FAH c.G233A (p.Trp78Ter)/c.554‐1G > T (p.?) |
16 | No | No | Acute hepatic failure: coagulopathy, thrombocytopenia | No | Asymptomatic |
| 17 | OTC | Cit: 2.5 μmol/L |
OTC c.928G > A (p.Glu310Lys) |
3 | Yes | Poor general clinical condition, respiratory distress, vomiting, seizures | Hyperammonemia (2484 μmol/L), coagulopathy, hypertransaminasemia | Hemodiafiltration, carglumic acid ammonia scavengers, l‐arginine, cofactors. | Death in neonatal period |
| 18 | OTC | Cit: 1.4 μmol/L |
OTC c.77G > A (p.Arg26Gln) |
5 | Yes | Somnolence, poor feeding, vomiting | Metabolic acidosis hyperammonemia (1505 μmol/L) | Hemodiafiltration, carglumic acid, and sodium phenylbutyrate | Severe–moderate cognitive impairment |
| 19 | CTLN1 | Cit: 1010 μmol/L |
ASS1 p.Val69Ala (c.206 T > C), p.Glu270Gln (c.808G > C)/p.Arg157His (c.470G > A) |
6 | Yes | Somnolence, decreased urine output, breathing difficulty. | Coagulopathy, hyperammonemia (800 μmol/L) | Hemodiafiltration | Normal neurodevelopment |
Abbreviations: CPT‐II, carnitine palmitoyltransferase type 2 deficiency; CTLN1, citrullinemia type 1; IEM, inborn error of metabolism; LCHADD, long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency; MCADD, medium‐chain acyl‐CoA dehydrogenase deficiency; MMA, methylmalonic acidemia; MMAHC, methylmalonic acidemia with homocystinuria; MSUD, maple syrup urinary disease; NBS, newborn screening; OTC, ornithine transcarbamylase deficiency; PA, propionic acidemia.
Genetic diagnosis was performed in all biochemically confirmed cases, being conclusive in all of them, except for two patients with HPA: in whom only a variant in one allele in the PAH gene was found and no variants in the DNAJC12 gens were identified. The different genotypes together with the geographical origin of the patients' parents are shown in Table 3. Analyses have detected 27 novel variants (supplementary material, S1 and S2), 18 pathogenic or likely pathogenic; 8 of them are variants with uncertain significance and one is potentially benign. The mutational spectrum included 17 potential missense variants, 3 small exonic insertion/deletions and 7 of them located in intronic sequence, and likely affecting the splicing process.
TABLE 3.
Genotype of patients diagnosed with an IEM by newborn screening in Madrid
| IEM (No. cases) | Gene | Genotype | No. cases | Country of origin |
|---|---|---|---|---|
| Benign HPA (51) | PAH | c.1208C > T (p.Ala403Val)/c.1208C > T (p.Ala403Val) | 4 | Morocco |
| c.60 + 5G > T /c.158G > A (p.Arg53His) | 2 | Spain | ||
| c.527G > T (p.Arg176Leu)/c.527G > T (p.Arg176Leu) | 2 | Dominican Republic | ||
| c.842C > T (p.Pro281leu)/c.1139C > T (p.Thr380Met) | 2 | Georgia. Spain | ||
| c.632delC (p.Pro211Hisfs*130)/c.734 T > C (p.Val245Ala) | 1 | Spain | ||
| c.261C > A (p.Ser87Arg)/c.527G > T (p.Arg176Leu) | 1 | Spain | ||
| c.441 + 5G > T /c.688G > A (p.Val230Ile) | 1 | Spain | ||
| c.1243G > A (p.Asp415Asn)/c.441 + 5G > T | 1 | Spain | ||
| c.165 T > G (p.Phe55Leu)/c.842 + 4A > G | 1 | Romania | ||
| c.842C > T (p.Pro281Leu)/c.898G > T (p.Ala300Ser) | 2 | Romania. Spain | ||
| c.734 T > C (p. Val 245Ala)/c.1241A > G (p.Tyr414Cys) | 1 | Spain | ||
| c.194 T > C (p.Ile65Thr)/c.158G > A (p.Arg53His) | 1 | Spain | ||
| c.158G > A (p.Arg53His)/c.510‐2A > G | 1 | Morocco | ||
| c.117C > G (p.Phe39Leu)/c.183C > G (p.Asn61Lys) | 1 | Spain | ||
| c.1045 T > C (p.Ser349Pro) | 1 | Spain | ||
| c.1243G > A (p.Asp415Asn)/c.158G > A (p.Arg53His) | 1 | Morocco | ||
| c.688G > A (p.Val230Ile)/c.1241A > G (p.Tyr414Cys) | 1 | Spain | ||
| c.1262 T > C (p.Ile421Thr)/c.116_118delTCT (p.Phe39del) | 1 | Spain | ||
| c.261C > A (p.Ser87Arg)/c.754C > T (p.Arg252Trp) | 1 | Spain | ||
| c.1045 T > C (p.Ser349Pro)/c.1139C > T (p.Thr380Met) | 1 | Spain | ||
| c.898G > T (p.Ala300Ser)/c.1241A > G (p.Tyr414Cys) | 1 | Spain | ||
| c.527G > T (p.Arg176Leu)/c.898G > T (p.Ala300Ser) | 1 | Spain | ||
| c.688G > A (p.Val230Ile)/c.1357*2delTAAAG (p.Ter453_Ser454delinsPro) | 1 | Spain‐Great Britain | ||
| c.165 T > G (p.Phe55Leu)/c.1066‐11G > A (p.Gln355_Tyr356ins3) | 1 | Paraguay | ||
| c.506G > A (p.Arg169His)/c.842C > T (p.Pro281Leu) | 1 | Georgia | ||
| c.444 + 5G > T/c.809G > A (p.Arg270Lys) | 1 | Spain | ||
| c.194 T > C (p.Ile65Thr)/c.688G > A (p.Val230Ile) | 1 | Spain | ||
| c.1066‐11G > A (p.Gln355_Tyr356ins3)/c.1259 G > T (Arg420Met) | 1 | Spain | ||
| c.510‐2A > G/c.158G > A (p.Arg53His) | 1 | Morocco | ||
| c.898G > T (p.Ala300Ser) /c.441 + 5G > T | 1 | Spain | ||
| c.165 T > G (p.Phe55Leu)/c.194 T > C (p.Ile65Thr) | 1 | Spain | ||
| c.827 T > C (p.Met276Thr)/c.1208C > T (p.Ala403Val) | 1 | Spain | ||
| c.838G > A (p.Glu280Lys)/c.1208C > T (p.Ala403Val) | 1 | Spain | ||
| c.592_613del22 (p.Tyr198Serfs*136)/ | 1 | Spain | ||
| c.116_118delTCT (p.Phe39del)/c.165 T > G (p.Phe55Leu) | 1 | Spain | ||
| c.60 + 5G > T /c.529G > A (p.Val177Met) | 1 | Spain | ||
| c.1241A > G (p.Tyr414Cys)/c.1139C > T (p.Thr380Met) | 1 | Spain | ||
| c.194 T > C (p.Ile65Thr)/c.1315 + 1G > A | 1 | Spain | ||
| c.782G > A (p.Arg261Gln)/c.194 T > C (p.Ile65Thr) | 1 | Spain | ||
| c.1066‐11G > A (p.Gln355_Tyr356ins3)/c.805A > C (p.Ile269Leu) | 1 | Spain | ||
| c.898G > T (p.Ala300Ser)/c.1065 + 3A > C | 1 | Spain | ||
| c.1208C > T (p.A403V)/c.441 + 5G > T | 1 | Spain | ||
| c.1066–11 G > A /c.1199 + 17 G > A | 1 | Spain | ||
| c.746 T > C (p.Leu249Pro)/c.890G > A (p.Arg297His) | 1 | Spain | ||
| Classic PKU (32) | PAH | c.842C > T (p.Pro281leu)/c.1162G > A (p.Val388Met) | 2 | Spain |
| c.754C > T (p.Arg252Trp)/c.1066‐11G > A (p.Gln355_Tyr356ins3) | 1 | Spain | ||
| c.185_189delTGACC (Leu62Profs*3)/c.441 + 5G > T | 1 | Paraguay | ||
| c.1243G > A (p.Asp415Asn)/c.442‐?_509 +?del (p.Gly148Trpfs*29?) | 1 | Colombia | ||
| c.781C > T (p.Arg261Ter)/c.1223G > A (p.Arg408Gln) | 1 | Spain | ||
| c.1222C > T (p.Arg408Trp)/c.1222C > T (p.Arg408Trp) | 1 | Romania | ||
| c.143 T > C (p.Leu48Ser)/c.441 + 5G > T | 1 | Spain | ||
| c.1027 T > G (p.Tyr343Asp)/c.1162G > A (p.Val388Met) | 1 | Spain | ||
| c.1045 T > C (p.Ser349Pro)/c.506_508delGCCinsCCA, p.(Arg169_His170delinsProAsn) | 1 | Spain | ||
| c.1055delG (p.Gly352Valfs*48)/c.1055delG (p.Gly352Valfs*48) | 1 | Morocco | ||
| c.204A > T (p.Arg68Ser)/c.136G > A (p.Gly46Ser) | 1 | Cuba | ||
| c.533A > G (p.Glu178Gly)/c.1222C > T (p.Arg408Trp) | 1 | Romania | ||
| c.1241A > G (p.Tyr414Cys)/c.1315 + 1G > A | 1 | Spain | ||
| c.165 T > G (p.Phe55Leu)/c.782G > A (p.Arg261Gln) | 1 | Ecuador/Cuba | ||
| c.500A > T (p.Asn167Ile)/c.1223G > A (p.Arg408Gln) | 1 | Germany/Spain | ||
| c.782G > A (p.Arg261Gln)/c.1162G > A (p.Val388Met) | 1 | Spain/Portugal | ||
| c.782G > A (p.Arg261Gln)/c.842C > T (p.Pro281Leu) | 1 | Spain | ||
| c.721C > T (p.Arg241Cys)/c.721C > T (p.Arg241Cys) | 1 | Morocco | ||
| c.439C > T (p.Pro147Ser)/c.727C > T (p.Arg243Ter) | 1 | Spain | ||
| c.441 + 5G > T /c.782G > A (p.Arg261Gln) | 1 | Spain | ||
| c.754C > T (p.Arg252Trp)/c.782G > A (p.Arg261Gln) | 1 | Bulgaria | ||
| c.60 + 5G > T /c.1055delG (p.Gly352Valfs*48) | 1 | Spain | ||
| c.842C > T (p.Pro281leu)/c.842C > T (p.Pro281leu) | 1 | Morocco | ||
| c.143 T > C (p.Leu48Ser)/c.1222C > T (p.Arg408Trp) | 1 | Romania | ||
| c.441 + 5G > T /c.1066‐11G > A (p.Gln355_Tyr356ins3) | 1 | Spain | ||
| c.1162G > A (p.Val388Met)/c.1162G > A (p.Val388Met) | 1 | Spain | ||
| c.561G > C (p.Trp187Cys)/c.1241A > G (p.Tyr414Cys) | 1 | Peru/Spain | ||
| c.441 + 5G > T /c.1028A > G (p.Tyr343Cys) | 1 | Spain | ||
| c.781C > T (p.Arg261Ter)/c.1262 T > C (p.Ile421Thr) | 1 | Spain | ||
| c.1067‐11G > A /c.1067‐11G > A | 1 | Morocco | ||
| c.1241A > G (p.Tyr414Cys)/c.1042C > G (p.Leu348Val) | 1 | Spain | ||
| DNAJC12 deficiency (4) | DNAJC12 | c.524G > A (p.Trp175Ter)/c.524G > A (p.Trp175Ter) | 2 | Spain |
| c.524G > A (p.Trp175Ter)/c.502 + 1G > C | 1 | Spain | ||
| c.524G > A (p.Trp175Ter)/c.298‐2A > C | 1 | Spain | ||
| Primapterinuria (2) | PCBD1 | c.259G > T (p.Glu87Ter) /c.259G > T (p.Glu87Ter) | 1 | Cape Verde |
| c.292C > T(p.Gln98Ter) /c.292C > T(p.Gln98Ter) | 1 | Spain | ||
| GA‐1 (12) | GCDH | c.1198G > A (p.Val400Met)/c.1198G > A (p.Val400Met) | 2 | Spain |
| c.1198G > A (p.Val400Met)/c.1240C > T (p.Arg402Trp) | 1 | Spain | ||
| c.1198G > A (p.Val400Met)/c.442G > T (p.Val148Phe) | 1 | Spain | ||
| c.278A > G (p.His93Arg)/c.278A > G (p.His93Arg) | 1 | Spain | ||
| c.877G > A (p.Ala293Thr)/c.877G > A (p.Ala293Thr) | 1 | Spain | ||
| c.877G > A (p.Ala293Thr)/c.1198G > A (p.Val400Met) | 1 | Spain | ||
| c.877G > A (p.Ala293Thr)/c.1210G > C (p.Ala404Pro) | 1 | Spain | ||
| c.946G > A (p.Ala304Thr)/c.1198G > A (p.Val400Met) | 1 | Spain | ||
| c.442G > T (p.Val148Phe)/c.463 T > C (p.Tyr1555His) | 1 | Spain | ||
| c.395G > A (p.Arg132Gln)/c.1204C > T (p.Arg402Trp) | 1 | Spain | ||
| c.1144G > A (p.Ala382Thr) /c.1204C > T (p.Arg402Trp) | 1 | Dominican Republic | ||
| MCG‐3 (7) | MCCC1 | c.1331G > A (p.Arg444His) /c.1008G > C (p.Met336Ileu) | 1 | Morocco |
| c.872 (p.Ala291Val) /c.1970 T > C (p.Ile657Thr) | 1 | Spain | ||
| MCCC2 | c.1015G > A (p.Val339Met)/c.1635dupT (p.Ser546Ter) | 1 | Spain | |
| c.1322 T > C (p.Ile441Thr)/c.129 + 3A > G | 1 | Spain | ||
| c.1015G > A (p.Val339Met)/c.641G > C (p.Gly214Ala) | 1 | Spain | ||
| 1423G > A (p.Gly475Arg)/c.1423G > A (p.Gly475Arg) | 1 | Morocco | ||
| c.804‐14 T > A /c.804‐14 T > A | 1 | Ecuador | ||
| PA (5) | PCCB | c.1218_1231del14ins12 (p.Gly407Argfs*14)/c.1218_1231del14ins12 (p.Gly407Argfs*14) | 3 | Spain (2). Spain‐Peru (1) |
| c.1218_1231del14ins12 (p.Gly407Argfs*14) /c.1173dupT (p.Val392Cysfs*2) | 1 | Spain | ||
| c.1606A > G (p.Asn536Asp) /c.1606A > G(p.Asn536Asp) | 1 | Spain | ||
| c.1173dupT(p.Val392Cysfs*2) /c.1173dupT(p.Val392Cysfs*2) | 1 | Spain | ||
| MAT (6) | MAT1A | c.791G > A (p.Arg264His) | 4 | Spain (3). Argentina (1) |
| c.776C > T (p.Ala259Val) | 1 | Spain | ||
| c.595C > T (p.Arg199Cys) /c.770G > A (p.Gly257Glu) | 1 | Spain | ||
| TYRSN1 (3) | FAH | c.554‐1G > T /c.554‐1G > T | 2 | Spain/Morocco |
| c.554‐1G > T /c.233G > A p.(Trp78Ter) | 1 | Spain | ||
| TYRSN3 (1) | HPD | c.778G > A (p.Gly260Arg)/c.1118A > T (p.Glu373Val) | 1 | Ecuador |
| MSUD (4) | BCKDHB | c.508C > T (p.Arg170Cys) /c.595_596delAG (p.Pro200Ter) | 1 | Spain |
| c.595_596delAG (p.Pro200Ter) /c.604G > A (p.Ala202Thr) | 1 | Spain‐Colombia | ||
| BCKDHA | c.370C > T (p.Arg124Trp)/c.743C > T (p.Ala248Val) | 1 | Paraguay | |
| DBT | c.(51 + 1_52–1)_(175 + 1_176–1)/c.(51 + 1_52–1)_(175 + 1_176–1) | 1 | El Salvador | |
| BCAT‐2 deficiency (2) | BCAT2 | c.1154_1160del7ins12 (p.Ala385Valfs*35)/c.1154_1160del7ins12 (p.Ala385Valfs*35) | 1 | Spain |
| c.762G > C (p.Trp254Cys) /c.923G > A (p.Trp308Ter) | 1 | Spain | ||
| HC (2) | CBS | c.572C > T (p.Thr191Met) /c.572C > T (p.Thr191Met) | 1 | Spain |
| c.770C > T (p.Thr257Met) /c.803 T > C (p.Leu268Pro) | 1 | Netherlands/Spain | ||
| Cystinuria (1) | SLC3A1 | c.797 T > C (p.Phe266Ser)/c.1400 T > C (p.Met467Thr) | 1 | Romania |
| OTC (2) | OTC | c.928G > A (p.Glu310Lys) | 1 | Spain |
| c.77G > A (p.Arg26Gln) | Venezuela | |||
| CTLN1 (2) | ASS1 | c.[267 T > C;808G > C] (p.Val69Ala + Glu270Gln) /c.805G > A (p.Val269Met) | 1 | Spain/Peru |
| c.[206 T > C;808G > C] (p.[Val69Ala;Glu270Gln]) /c.470G > A (p.Arg157His) | 1 | Spain | ||
| HMGCLD (1) | HMGCL | c.109G > T (p.Glu37Ter) /c.785G > A (p.Gly262Glu) | 1 | Spain/Argentina |
| MCADD (43) | ACADM | c.985A > G (p.Lys329Glu)/c.985A > G (p.Lys329Glu) | 22 |
Spain (19). Romania (2) Peru (1) |
| c.985A > G (p.Lys329Glu)/c.638C > A (p.Thr228Asn) | 7 | Spain | ||
| c.638C > A (pThr228Asn)/c.999_1011dup13 (p.Glu338Ter) | 2 | Spain | ||
| c.985A > G (p.Lys329Glu)/c.626C > T (p.Pro209Leu) | 2 | Spain | ||
| c.985A > G (p.Lys329Glu)/c.351A > C (p.Thr117Thr) | 1 | Romania/Colombia | ||
| c.985A > G (p.Lys329Glu)/c.799G > A (p.Gly267Arg) | 1 | Spain | ||
| c.985A > G (p.Lys329Glu)/c.250C > T (p.Leu84phe) | 1 | Spain/Canada | ||
| c.985A > G (p.Lys329Glu)/c.946‐2A > C | 1 | Spain | ||
| c.985A > G (p.Lys329Glu)/c.609A > C (p.Leu203Phe) | 1 | Spain | ||
| c.985A > G (p.Lys329Glu)/c.127G > A (p.Glu43Lys) | 1 | Spain | ||
| c.985A > G (p.Lys329Glu)/c.599 + 3A > G | 1 | Spain/Paraguay | ||
| c.351A > C (p.Thr117Thr)/c.503A > C (p.Asp168Ala) | 1 | Spain | ||
| c.338C > A (p.Ala113Asp)/c.940G > C (p.Val314Leu) | 1 | Ecuador | ||
| c.1247 T > C (p.Ile416Thr)/c.778_782delGAAAA (p.Glu260Cysfs*5) | 1 | Paraguay | ||
| VLCAD (13) | ACADVL | c.848 T > C (p.Val283Ala)/c.1220G > C (p.Gly407Ala) | 2 | Spain |
| c.848 T > C (p.Val283Ala)/c.685 > T (p.Arg229Term) | 2 | Morocco | ||
| c.848 T > C (p.Val283Ala)/c.848 T > C (p.Val283Ala) | 1 | Spain | ||
| c.848 T > C (p.Val283Ala)/c.996delT (p.Ala333Profs*20) | 1 | Venezuela | ||
| c.761G > A (p.Gly254Asp)/c.761G > A (p.Gly254Asp) | 1 | Spain | ||
| c.520G > A (p.Val174Met)/c.1097G > A;c.1844G > A (p.Arg366His;p.Arg615Gln) | 1 | Spain | ||
| c.199A > T (p.Lys67Term)/c.1121A > C (p.His374Pro) | 1 | Germany‐Spain | ||
| c.138 + 2 T > C /c.1366C > T (p.Arg456Cys) | 1 | Spain | ||
| c.1367G > A (p.Arg456His)/c.1678 + 19_1678 + 31del13 | 1 | Spain | ||
| c.1174G > C (p.Val392Leu)/c.1752‐2_1755del6 | 1 | Spain | ||
| c.1077G > A (p.Ala359Ala)/c.683 T > C (p.Ile228Thr) | 1 | Italy‐Spain | ||
| LCHADD (2) | HADHA | c.1528G > C (p.Glu510Gln)/c.1915_1918delTATC (p.Tyr639Argfs*4) | 1 | Spain |
| c.453 + 1G > A (p.Met106fs)/c.453 + 1G > A (p.Met106fs) | 1 | Ecuador | ||
| SPCD (11) | SLC22A5 | c.845G > A (p.Arg282Gln) /c.845G > A (p.Arg282Gln) | 1 | Ecuador |
| c.845G > A (p.Arg282Gln) /c.1392_1409del18ins2 (p.Val465Thrfs*29) | 1 | Bolivia/Ecuador | ||
| c.806delT (p.Leu269Hisfs*27)/c.845G > A (p.Arg282Gln) | 1 | Spain‐Argentina | ||
| c.760C > T (p.Arg254Ter)/C.1400C > G (p.Ser467Cys) | 1 | China | ||
| c.743 T > C (p.Leu248Pro)/c.806delT (p.Leu269Hisfs*27) | 1 | Spain | ||
| c.680G > A (p.Arg227His)/c.824 + 1G > T | 1 | Italy‐Spain | ||
| c.447C > G (p.Phe149Leu)/c.680G > A (Arg227His) | 1 | Spain | ||
| c.419G > A (p.Trp140Ter)/c.845G > A (p.Arg282Gln) | 1 | Peru | ||
| c.364G > T (p.Asp122Tyr)/c.791C > G (Thr264Arg) | 1 | Spain | ||
| c.1345 T > G (p.Tyr449Asp)/c.1072 T > A (p.Tyr358Asn) | 1 | Dominican Republic | ||
| c.646G > C (p.Val216Leu)/c.646G > C (p.Val216Leu) | 1 | Morocco | ||
| CPT II (2) | CPT2 | c.1547 T > C (p.Phe516Ser)/c.122_130del9(p.Pro41_Met43del) | 1 | Colombia‐Spain |
| c.587C > T (p.Pro196Leu)/c.587C > T (p.Pro196Leu) | 1 | Spain | ||
| MADD (1) | ETFB | c.145G > C (p.Ala49Pro) /c.343_345delGAG (p.Glu115del) | 1 | Spain |
| CPT I (1) | CPT1A | c.2125G > A (p.Gly709Arg) /c.1948G > A (p.Gly650Ser) | 1 | Spain |
| MMAHC (7) | MMACHC | c.271dupA (p.Arg91Lysfs*14)/c.271dupA (p.Arg91Lysfs*14) | 4 |
Spain (2) Morocco (2) |
| c.271dupA (p.Arg91Lysfs*14)/c.440G > A (Gly147Asp) | 1 | Spain | ||
| c.271dupA (p.Arg91Lysfs*14)/c.464G > A (p.Gly155Glu) | 1 | Spain | ||
| MMADHC | c.748C > T (p.Arg250Ter)/c.748C > T (p.Arg250Ter) | 1 | Spain | |
| MMA (4) | MMUT | c.322C > T (p.Arg108Cys)/c.2026G > A (p.Ala676Thr) | 1 | Spain |
| c.655A > T (p.Asn219Tyr)/c.2206C > T (p.Leu736Phe) | 1 | Bulgaria | ||
| MMAB | c.220G > T (p.Glu74Ter)/c.548A > T (p.His183Leu) | 1 | Spain | |
| c.662 T > G (p.Phe221Cys)/c.569G > A (p.Arg190His) | 1 | Spain |
Abbreviations: BCAT‐2, branched‐chain amino acid transferase 2 deficiency; CPT‐I, carnitine palmitoyltransferase type 1 deficiency; CPT‐II, carnitine palmitoyltransferase type 2 deficiency; CTLN1, citrullinemia type 1; GA‐1, glutaric aciduria type 1; HC, homocystinuria; HMG‐CLD, 3‐hydroxy‐3‐methylglutaryl‐CoA lyase deficiency; HPA, hyperphenylalaninemia; IEM, inborn error of metabolism; LCHADD, long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency; MADD, multiple acyl‐coA dehydrogenation deficiency; MAT, hypermethioninemia; MCADD, medium‐chain acyl‐CoA dehydrogenase deficiency; MCG‐3:3‐methylcrotonyl‐CoA carboxylase deficiency; MMA, methylmalonic acidemia; MMAHC, methylmalonic acidemia with homocystinuria; MSUD, maple syrup urinary disease; OTC, ornithine transcarbamylase deficiency; PA, propionic acidemia; PKU, phenylketonuria; SPCD, systemic primary carnitine deficiencies; TYRSN‐1, tyrosinemia type I; TYRSN‐3, tyrosinemia type 3; VLCAD, very long‐chain acyl‐CoA dehydrogenase deficiency.
4. DISCUSSION
In our population, 26 different IEM have been detected, whereas pathogenic variants have been identified in 32 different genes.
An IEM was diagnosed in 1/2670 newborns, a remarkably similar rate was found in other studies performed in our Country (in the region of Galicia: 1/2060, excluding benign HPA 17 ; in the region of Aragon: 1/2573 18 ; in the region of Murcia: 1/1884, including Cystic Fibrosis 19 ). This rate is also similar in other Western European Countries: Portugal: 1/2396, 20 Germany: 1/2712, 21 or Italy: 1/2000 22 ). As in other programs, the conditions with the highest incidence were HPA (1/6587) and MCAD deficiencies (1/13787). 9 , 23 A recent systematic review and meta‐analysis reported a global worldwide birth prevalence of PAH deficiency of 1/15625, being higher in Europe (1/8771). 24
The positive predictive value was lower than in other reports in our Country, like in Galicia (76.11%), 17 where they performed second tier tests and collected blood and urine samples simultaneously of all newborns; but comparable to other programs, where second tier tests were also not requested (20%). 19 Nevertheless, the ENBS allowed the diagnosis of other entities different from IEM as vitamin B12 deficiencies, or different maternal diagnoses, which have not been included in this report. These conditions have already been reported in other programs. 25 , 26
Most of the cases benefited from presymptomatic diagnosis. Only 19 patients (8.5%) displayed symptoms before the result of the NBS was available. However, for some fatty acid oxidations disorders, organic acidemias and urea cycle disorders, at least half of the patients presented with clinical symptoms (LCHADD: 1/2, CPT‐II: 1/2, PA: 5/6, MMAHC: 3/7, MSUD: 2/4, OTC deficiency 2/2). Only one patient with MCADD, who presented with remarkable high octanoylcarnitine (C8) levels, displayed clinical symptoms (hypoglycemia and hypotonia). He harbored a homozygous pathogenic variant c.985A > G in the ACADM gene, which has been associated with more severe cases and higher levels of neonatal C8 and urinary acylglycines. 27 , 28 One of the patients diagnosed with LCHADD had a very early and fatal onset. This disease usually displays immediate complications, but recent data have shown that outcomes can be favorable if early diagnosis and strict dietary regime are initiated. 29 , 30 A similar scenario is evident in CPT‐II deficiency, with frequent sudden death or severe metabolic decompensation. 31
For PA and MMA (including MMAHC) several cases presented with neurological deterioration in the first‐second weeks of life. It is well known that their clinical course generally starts with an acute metabolic decompensation in the neonatal period, 32 that frequently leads to irreversible neurological damage. 33 However, as in our cases, most of the patients are already symptomatic before NBS results can be available. 34 , 35 Furthermore, even when early diagnosis and optimal metabolic control are achieved, disease progression occurs. 36 It has also been postulated that NBS does not have an effect on diagnosis of PA as it is hardly ever asymptomatic. 37 However, as last guidelines stated, 38 we consider necessary to establish a prompt diagnosis in children with suggestive clinical signs and symptoms. On the other hand, for GA‐1, as in our series, NBS usually allows the presymptomatic diagnosis, and it has been proven to be effective in preventing the progressive neurological deterioration. 39 , 40 Two of the three patients diagnosed with MSUD were symptomatic, and both have displayed neurological impairment in the follow‐up. Indeed, detection of this disorder before the occurrence of severe symptoms 41 has been reported and NBS has demonstrated to avoid neurological deterioration and to clearly improve prognosis of MSUD patients. 42 , 43 Diagnosis of OTC by NBS is feasible as low blood citrulline levels can be detected in this condition. 44 Notwithstanding, its inclusion in NBS programs remains controversial as hypocitrullinemia may not be present, especially in late onset forms. 45 Based on our data, OTC should be evaluated and ruled‐out when low citrulline levels are detected to diagnose severe cases which can be potentially fatal, as our patient who died on the third day of life. Finally, one patient with Tyr‐I also displayed clinical symptoms with an acute liver failure. For this IEM, early diagnosis and treatment has also proven to have a benefit in the natural history although patients seem to remain with several neurological disturbances. 46 , 47
Mean time to clinical referral varied notably among the different IEMs. As shown in Table 1, time was longer for conditions considered “mild” as benign HPA, MCG‐3, or SPCD, where samples are frequently repeated before referral. The routine screening of MCG‐3 condition is controversial. In general, authors consider that longer investigations and follow‐up are needed to establish its indication. 48 Besides, based on our data, we consider mandatory the accurate evaluation of cases with abnormal C5OH, as our patient with HMG‐CoA lyase deficiency presented with similar C5OH values as those with MCG‐3, without other biochemical abnormalities. For this condition, novel biomarkers have recently been identified 49 ; organic acid analysis in urine is necessary as the second tier‐test for confirmation of this disease. Detection of HMG‐CoA lyase deficiency is essential as about half of the patients become symptomatic within the neonatal period. 50
The death rate in our population was 1.3% (3/222), a bit lower than observed in other series. 17 , 51 Early mortality data for PA, LCHADD and OTC was 17, 50, and 50%, respectively. It is essential to report also longitudinal outcome data.
In our program, genetic diagnosis not only has confirmed all the biochemical cases (except for two) but also has allowed to detect novel IEM, as HPA due to DNAJC12 pathogenic variants and BCAT‐2 deficiency. These new two entities present with a heterogeneous clinical spectrum, 52 , 53 and description of the cases with long‐term studies are essential to better understand the natural history of these pathologies. Other recent studies have also established that molecular analyses can increase the number of pathologies from NBS, 54 and some authors even postulate that whole exome sequencing could be considered as a follow‐up test for MS/MS positive individuals, offering an early and accurate definitive diagnosis. 55 , 56
For HPA, as it has been previously described, 57 molecular characterization was heterogeneous. We have identified close to 60 different pathogenic variants, all of them with a low prevalence. More than 950 variants in the PAH have been identified, being the most one, the missense change c.1222C > T (23% of all variants). 58 However, in our patients, it was only found in four alleles. In our series, the most prevalent variant was the c.1208C > T associated with benign HPA, and the second one the variant c.842C > T, which was not identified in a previous study conducted in our Country. 59
Concerning MCADD, the most common variant was c.985A > G, found in 59 of 86 alleles (66%). In Galicia, the proportion was higher with a prevalence of 86% (78 out of 90 alleles). 60 In fact, this variant is the most frequently reported in literature and occurs at a frequency up to 90% of disease alleles in symptomatic MCADD patients of European origin. 27 However, as NBS has enabled the detection of patients with milder phenotype, the molecular heterogeneity of this defect has increased. Consequently, patients diagnosed within the screening generally show a lower proportion (30–71%) of that common variant. 27 , 61 In addition, a good correlation between genotype and enzyme function has recently been demonstrated. 62
In conclusion, in 9 years, 222 IEM have been detected with a large clinical, biochemical, and molecular heterogeneity. Most of the cases benefited from presymptomatic diagnosis but with quite notable differences among the different disorders and 27 novel variants have been reported.
CONFLICT OF INTEREST
The authors declare no potential conflict of interest.
AUTHOR CONTRIBUTIONS
Consuelo Pedrón‐Giner: Had the original idea and contributed to planning the research design, methods, and preparation of manuscript. Álvaro Martín‐Rivada and Laura Palomino Pérez: Contributed to data acquisition, carrying out aspects of the methods and statistical analysis, and writing the draft of the manuscript. Belén Pérez: Performed, reviewed, and discussed data concerning molecular and genetic diagnosis. All authors have been involved in drafting the article and have expressed their agreement to submission.
INFORMED CONSENT
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
Supporting information
Supplementary Material S1 Novel variants detected after the Implementation of Expanded Newborn Screening in Madrid.
dbSNP: Database for Single Nucleotide Polymorphisms
PhiloP
GVGD: Grantham Variation ‐ Grantham Deviation
SIFT: Scale‐invariant feature transform
CSVS: Collaborative Spanish Variant Server
MAF: Minimum allele frequency
GnomAD: Genome Aggregation Database
ACMG: American College of Medical Genetics
Supplementary Material S2 Novel variants affecting intronic sites detected after the Implementation of Expanded Newborn Screening in Madrid.
SSF: Splicing Sequences Finder
MaxEnt: Maximum Entropy Modeling
NNSPLICE: Splice Site Prediction by Neural Network
CSVS: Collaborative Spanish Variant Server
MAF: Minimum allele frequency
GnomAD: Genome Aggregation Database
ACMG: American College of Medical Genetics
Martín‐Rivada Á, Palomino Pérez L, Ruiz‐Sala P, et al. Diagnosis of inborn errors of metabolism within the expanded newborn screening in the Madrid region. JIMD Reports. 2022;63(2):146-161. doi: 10.1002/jmd2.12265
Funding informationThis work was funded to BP by the Carlos III Institute (ISCIII), European Regional Development Fund (PI19/01155), Consejería de Educación, Juventud y Deporte, Comunidad de Madrid (B2017/BMD3721).
Communicating Editor: Jaak Jaeken
DATA AVAILABILITY STATEMENT
Data archiving is not mandated but data will be made available on reasonable request.
REFERENCES
- 1. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338‐343. [PubMed] [Google Scholar]
- 2. Gil Ortega D, Fernández SA. Programas de cribado en España. In: González Lamuño D, Aldámiz‐Echevarría L, Couce Pico ML, eds. Universidade de Santiago de Compostela, Servizo de Publicacións e Intercambio Científico. 2nd ed. Manual Clínico del Cribado Metabólico; 2015:43‐55. [Google Scholar]
- 3. Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis. 1990;13:321‐324. [DOI] [PubMed] [Google Scholar]
- 4. Rashed MS, Bucknall MP, Little D, et al. Screening blood spots for inborn errors of metabolism by electrospray tandem mass spectrometry with a microplate batch process and a computer algorithm for automated flagging of abnormal profiles. Clin Chem. 1997;43:1129‐1141. [PubMed] [Google Scholar]
- 5. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem. 2003;49:1797‐1817. [DOI] [PubMed] [Google Scholar]
- 6. Therrell BL, Padilla CD, Loeber JG, et al. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015;39:171‐187. [DOI] [PubMed] [Google Scholar]
- 7. Watsson MS, Mann MY, Lloyd‐Puryear MA, Rinaldo P, Howell R, American College of Medical Genetics Newborn Screening Expert Group . Newborn screening: toward a uniform screening panel and system‐executive summary. Pediatrics. 2006;117:s296‐s307. [DOI] [PubMed] [Google Scholar]
- 8. Bodamer OA, Hoffmann GF, Lindner M. Expanded newborn screening in Europe 2007. J Inherit Metab Dis. 2007;30:439‐444. [DOI] [PubMed] [Google Scholar]
- 9. Loeber JG. Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis. 2007;30(4):430‐438. [DOI] [PubMed] [Google Scholar]
- 10. Loeber G, Platis D, Zetterström RH, et al. Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments since 2010. Int J Neonatal Screen. 2021;7:15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Boletín Oficial del Estado . Orden SSI/2065/2014, de 31 de octubre, por la que se modifican los anexos I, II y III del Real Decreto 1030/2006, de 15 de septiembre, por el que se establece la cartera de servicios comunes del Sistema Nacional de Salud y el procedimiento para su actualización. 2014.
- 12. Programas de Cribado Neonatal en España . Actualización y Propuestas de Futuro. Documento consenso. Real Patronato sobre Discapacidad. Ministerio de Sanidad y Política Social; 2010. [Google Scholar]
- 13. Castiñeras DE, Couce ML, Marn JL, González‐Lamuño D, Rocha H. Situación actual del cribado neonatal de enfermedades metabólicas en España y en el mundo. An Pediatr (Barc). 2019;91(2):128.e1‐128.e14. [DOI] [PubMed] [Google Scholar]
- 14. Boletín Oficial de la Comunidad de Madrid (BOCM) . ORDEN 237/2010, de 5 de mayo, por la que se dictan normas en relación a las pruebas de cribados para detección precoz de enfermedades y prevención de minusvalías en recién nacidos. 2010.
- 15. Clinical and Laboratory Standards Institute . Newborn screening by tandem mass spectrometry. CLSI Guideline NBS04. 2nd ed. Clinical and Laboratory Standards Institute; 2017. [Google Scholar]
- 16. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405‐424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Couce ML, Castiñeiras DE, Bóveda MD, et al. Evaluation and long‐term follow‐up of infants with inborn errors of metabolism identified in an expanded screening programme. Mol Genet Metab. 2011;104:470‐475. [DOI] [PubMed] [Google Scholar]
- 18. García Jiménez MC, Monge Galindo L, Roncalés SP. Cribado neonatal metabólico ampliado. Bol Pediatr Arag Rioj Sor. 2015;45:47‐54. [Google Scholar]
- 19. Juan‐Fita MJ, Egea‐Mellado JM, González‐Gallego I, Moya‐Quiles MR, Fernández‐Sánchez A. Cribado neonatal ampliado en la Región de Murcia. Experiencia de tres años. Med Clin (Barc). 2012;139(13):566‐571. [DOI] [PubMed] [Google Scholar]
- 20. Vilarinho L, Rocha H, Sousa C, et al. Four years of expanded newborn screening in Portugal with tandem mass spectrometry. J Inherit Metab Dis. 2010;33(Suppl 3):S133‐S138. [DOI] [PubMed] [Google Scholar]
- 21. Harms E, Olgemöller B. Neonatal screening for metabolic and endocrine disorders. Dtsch Arztebl Int. 2011;108:11‐22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. La Marca G, Malvagia S, Casetta B, et al. Progress in expanded newborn screening for metabolic conditions by LC‐MS/MS in Tuscany: update on methods to reduce false tests. J Inherit Metab Dis. 2008;31:S395‐S404. [DOI] [PubMed] [Google Scholar]
- 23. Wilcken B, Haas M, Joy P, et al. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics. 2009;124:e241‐e248. [DOI] [PubMed] [Google Scholar]
- 24. Foreman PK, Margulis AV, Alexander K, et al. Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta‐analysis. Orphanet J Rare Dis. 2021;16:253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Scolamiero E, Domenico Villani GR, Ingenito L, et al. Maternal vitamin B12 deficiency detected in expanded newborn screening. Clin Biochem. 2014;47:312‐317. [DOI] [PubMed] [Google Scholar]
- 26. Crombez EA, Cederbaum SD, Spector E, et al. Maternal glutaric acidemia, type I identified by newborn screening. Mol Genet Metab. 2008;94:132‐134. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Gramer G, Haege G, Fang‐Hoffmann J, et al. Medium‐chain acyl‐CoA dehydrogenase deficiency: evaluation of genotype‐phenotype correlation in patients detected by newborn screening. JIMD Rep. 2015;23:101‐112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Waddell L, Wiley V, Carpenter K, et al. Medium‐chain acyl‐CoA dehydrogenase deficiency: genotype‐biochemical phenotype correlations. Mol Genet Metab. 2006;87(1):32‐39. [DOI] [PubMed] [Google Scholar]
- 29. Karall D, Brunner‐Krainz M, Kogelnig K, et al. Clinical outcome, biochemical and therapeutic follow‐up in 14 Austrian patients with long‐chain 3‐Hydroxy acyl CoA dehydrogenase deficiency (LCHADD). Orphanet J Rare Dis. 2015;10:21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Immonen T, Turanlahti M, Paganus A, Keskinen P, Tyni T, Lapatto R. Earlier diagnosis and strict diets improve the survival rate and clinical course of long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency. Acta Paediatr. 2016;105(5):549‐554. [DOI] [PubMed] [Google Scholar]
- 31. Bo R, Musha I, Yamada K, et al. Need for strict clinical management of patients with carnitine palmitoyltransferase II deficiency: experience with two cases detected by expanded newborn screening. Mol Genet Metab Rep. 2020;24:100611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Kölker S, García Cazorla A, Valayannopoulos V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis. 2015;38:1041‐1057. [DOI] [PubMed] [Google Scholar]
- 33. Haijes HA, Molema F, Langeveld M, et al. Retrospective evaluation of the Dutch pre‐newborn screening cohort for propionic acidemia and isolated methylmalonic acidemia: what to aim, expect, and evaluate from newborn screening? J Inherit Metab Dis. 2020;43(3):424‐437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Leonard JV, Vijayaraghavan S, Walter JH. The impact of screening for propionic and methylmalonic acidemia. Eur J Pediatr. 2003;612:S21‐S24. [DOI] [PubMed] [Google Scholar]
- 35. Hörster F, Kölker S, Loeber JG, Cornel MC, Hoffmann GF, Burgard P. Newborn screening programmes in Europe, arguments and efforts regarding harmonisation: focus on organic acidurias. JIMD Rep. 2016;32:105‐115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Dimitrov B, Molema F, Williams M, et al. Organic acidurias: major gaps, new challenges, and a yet unfulfilled promise. J Inherit Metab Dis. 2020;44:9‐21. doi: 10.1002/jimd.12254 [DOI] [PubMed] [Google Scholar]
- 37. Dionisi‐Vici C, Deodato F, Röschinger W, Rhead W, Wilcken B. “Classical” organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: long‐term outcome and effects of expanded newborn screening using tandem mass spectrometry. J Inherit Metab Dis. 2006;29(2–3):383‐389. [DOI] [PubMed] [Google Scholar]
- 38. Forny P, Hörster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis. 2021;44:1‐27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Couce ML, López‐Suárez O, Bóveda MD, et al. Glutaric aciduria type I: outcome of patients with early‐versus late‐diagnosis. Eur J Paediatr Neurol. 2013;17(4):383‐389. [DOI] [PubMed] [Google Scholar]
- 40. Bijarnia S, Wiley V, Carpenter K, Christodoulou J, Ellaway CJ, Wilcken B. Glutaric aciduria type I: outcome following detection by newborn screening. J Inherit Metab Dis. 2008;31:503‐507. [DOI] [PubMed] [Google Scholar]
- 41. Heldt K, Schwahn B, Marquardt I, Grotzke M, Wendel U. Diagnosis of MSUD by newborn screening allows early intervention without extraneous detoxification. Mol Genet Metab. 2005;84(4):313‐316. [DOI] [PubMed] [Google Scholar]
- 42. Stroek K, Boelen A, Bouva MJ, et al. Evaluation of 11 years of newborn screening for maple syrup urine disease in The Netherlands and a systematic review of the literature: strategies for optimization. JIMD Rep. 2020;54(1):68‐78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Couce ML, Ramos F, Bueno MA, et al. Evolution of maple syrup urine disease in patients diagnosed by newborn screening versus late diagnosis. Eur J Paediatr Neurol. 2015;19(6):652‐659. [DOI] [PubMed] [Google Scholar]
- 44. Brusilow SW, Horwich AL. In: Scriver CR, Beaudet AL, Valle D, Sly WS, eds. The Metabolic and Molecular Bases of Inherited Disease. McGraw‐Hill; 2001:1909‐1963. [Google Scholar]
- 45. Cavicchi C, Malvagia S, la Marca G, et al. Hypocitrullinemia in expanded newborn screening by LC‐MS/MS is not a reliable marker for ornithine transcarbamylase deficiency. J Pharm Biomed Anal. 2009;49(5):1292‐1295. [DOI] [PubMed] [Google Scholar]
- 46. McKiernan PJ, Preece MA, Chakrapani A. Outcome of children with hereditary tyrosinaemia following newborn screening. Arch Dis Child. 2015;100(8):738‐741. [DOI] [PubMed] [Google Scholar]
- 47. Couce ML, Sánchez‐Pintos P, Aldámiz‐Echevarría L, et al. Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain. Medicine. 2019;98(39):e17303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Wang H, Liu S, Wang B, et al. 3‐Methylcrotonyl‐CoA carboxylase deficiency newborn screening in a population of 536,008: is routine screening necessary? J Pediatr Endocrinol Metab. 2019;32(12):1321‐1326. [DOI] [PubMed] [Google Scholar]
- 49. Václavík J, Coene KLM, Vrobel I, et al. Structural elucidation of novel biomarkers of known metabolic disorders based on multistage fragmentation mass spectra. J Inherit Metab Dis. 2018;41(3):407‐414. [DOI] [PubMed] [Google Scholar]
- 50. Václavík J, Mádrová L, Kouřil Š, et al. A newborn screening approach to diagnose 3‐hydroxy‐3‐methylglutaryl‐CoA lyase deficiency. JIMD Rep. 2020;54(1):79‐86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Frazier DM, Millington DS, McCandless SE, et al. The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005. J Inherit Metab Dis. 2006;29:76‐85. [DOI] [PubMed] [Google Scholar]
- 52. Knerr I, Colombo R, Urquhart J, et al. Expanding the genetic and phenotypic spectrum of branched‐chain amino acid transferase 2 deficiency. J Inherit Metab Dis. 2019;42(5):809‐817. [DOI] [PubMed] [Google Scholar]
- 53. Gallego D, Leal F, Gámez A, et al. Pathogenic variants of DNAJC12 and evaluation of the encoded cochaperone as a genetic modifier of hyperphenylalaninemia. Hum Mutat. 2020;41(7):1329‐1338. [DOI] [PubMed] [Google Scholar]
- 54. Navarrete R, Leal F, Vega AI, et al. Value of genetic analysis for confirming inborn errors of metabolism detected through the Spanish neonatal screening program. Eur J Hum Genet. 2019;27(4):556‐562. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Morava E, Baumgartner M, Patterson M, Peters V, Rahman S. Newborn screening: to WES or not to WES, that is the question. J Inherit Metab Dis. 2020;43(5):904‐905. [DOI] [PubMed] [Google Scholar]
- 56. Adhikari AN, Gallagher RC, Wang Y, et al. The role of exome sequencing in newborn screening for inborn errors of metabolism. Nat Med. 2020;26(9):1392‐1397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Wettstein S, Underhaug J, Perez B, et al. Linking genotypes database with locus‐specific database and genotype‐phenotype correlation in phenylketonuria. Eur J Hum Genet. 2015;23:302‐309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Blau N. Genetics of phenylketonuria: then and now. Hum Mutat. 2016;37(6):508‐515. [DOI] [PubMed] [Google Scholar]
- 59. Aldámiz‐Echevarría L, Llarena M, Bueno MA, et al. Molecular epidemiology, genotype‐phenotype correlation and BH4 responsiveness in Spanish patients with phenylketonuria. J Hum Genet. 2016;61(8):731‐744. [DOI] [PubMed] [Google Scholar]
- 60. Couce ML, Sánchez‐Pintos P, Diogo L, et al. Newborn screening for medium‐chain acyl‐CoA dehydrogenase deficiency: regional experience and high incidence of carnitine deficiency. Orphanet J Rare Dis. 2013;8:102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Arnold GL, Saavedra‐Matiz CA, Galvin‐Parton PA, et al. Lack of genotype‐phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York state. Mol Genet Metab. 2010;99:263‐268. [DOI] [PubMed] [Google Scholar]
- 62. Tucci S, Wagner C, Grünert SC, et al. Genotype and residual enzyme activity in medium‐chain acyl‐CoA dehydrogenase (MCAD) deficiency: are predictions possible? J Inherit Metab Dis. 2021;44:916‐925. doi: 10.1002/jimd.12368 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary Material S1 Novel variants detected after the Implementation of Expanded Newborn Screening in Madrid.
dbSNP: Database for Single Nucleotide Polymorphisms
PhiloP
GVGD: Grantham Variation ‐ Grantham Deviation
SIFT: Scale‐invariant feature transform
CSVS: Collaborative Spanish Variant Server
MAF: Minimum allele frequency
GnomAD: Genome Aggregation Database
ACMG: American College of Medical Genetics
Supplementary Material S2 Novel variants affecting intronic sites detected after the Implementation of Expanded Newborn Screening in Madrid.
SSF: Splicing Sequences Finder
MaxEnt: Maximum Entropy Modeling
NNSPLICE: Splice Site Prediction by Neural Network
CSVS: Collaborative Spanish Variant Server
MAF: Minimum allele frequency
GnomAD: Genome Aggregation Database
ACMG: American College of Medical Genetics
Data Availability Statement
Data archiving is not mandated but data will be made available on reasonable request.